NCT01858935COMPLETEDanonymous

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection, a Vitamin A-Coupled Lipid Nanoparticle Containing siRNA Against HSP47, in Healthy Normal Subjects

Sponsor

Source record

Bristol-Myers Squibb

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

ND-L02-s0201 Injection, Placebo

Indication / condition

AI-normalized

Healthy

Intervention

Source record

ND-L02-s0201 Injection, Placebo

Source & freshness

Source record

NCT ID

NCT01858935

Original source

ClinicalTrials.gov

Source last updated

May 11, 2017

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT01858935

Title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection, a Vitamin A-Coupled Lipid Nanoparticle Containing siRNA Against HSP47, in Healthy Normal Subjects

Sponsor

Bristol-Myers Squibb

Status

COMPLETED

Phase

PHASE1

Condition raw

Healthy

Condition normalized

Healthy

Modality raw

small molecule

Modality normalized

small molecule

Target raw

ND-L02-s0201 Injection, Placebo

Target normalized

ND-L02-s0201 Injection, Placebo

Interventions

ND-L02-s0201 Injection, Placebo

Public preview

Source record

This study is to evaluate the safety, tolerability, and pharmacokinetics of ND-L02-s0201 in normal, healthy, subjects

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection, a Vitamin A-Coupled Lipid Nanoparticle Containing siRNA Against HSP47, in Healthy Normal Subjects

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01858935

Status

COMPLETED

Phase

PHASE1

Sponsor

Bristol-Myers Squibb

Executive brief

Investment-Ready Snapshot

This study is to evaluate the safety, tolerability, and pharmacokinetics of ND-L02-s0201 in normal, healthy, subjects

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedMay 11, 2017

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01858935

Indication

Healthy

Modality

small molecule

Target

ND-L02-s0201 Injection, Placebo

Intervention

ND-L02-s0201 Injection, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.